#United States #San Diego #Abbott #AFib #Amulet 360

Abbott's Amulet 360™: One-Year Results Showcase its Efficacy in Stroke Reduction

In a recent announcement, Abbott (NYSE: ABT), a prominent name in global healthcare, revealed the one-year findings of its Amulet 360™ Left Atrial Appendage (LAA) Occluder from the landmark VERITAS study. These results were presented at the Transcatheter Cardiovascular Therapeutics conference in San Diego, California, on November 1, 2026, and simultaneously published in JACC Cardiovascular Interventions.

The Amulet 360™ device is specially designed to mitigate the risk of stroke and serious blood clot complications in patients suffering from atrial fibrillation (AFib) that is not related to heart valve issues. The investigational device has garnered attention for its impressive closure rates of the left atrial appendage, a common source of blood clots that lead to strokes.

Key Findings from the VERITAS Study

The late-breaking data from this pivotal study indicates that complete closure of the LAA was achieved in an astonishing 96.3% of the patients evaluated through transesophageal echocardiography (TEE), a specialized heart ultrasound test used to assess the effectiveness of the procedure. Additional long-term results revealed:

• - Over 98% of patients remained free from ischemic strokes or systemic embolism through the first year.
• - More than 99% avoided pericardial effusion requiring intervention.
• - Over 98% were free from cardiovascular-related mortality.
• - Major bleeding events were reported in only 6.6% of patients, indicating a high safety profile.

Dr. DJ Lakkireddy, the Executive Medical Director at the Kansas City Heart Rhythm Institute, described the trial results as highly encouraging, emphasizing that the sustained high rates of complete closure over the year provide significant reassurance for healthcare providers committed to reducing stroke risks in non-valvular atrial fibrillation patients.

Innovative Design Enhancements

The Amulet 360 device incorporates two main components that set it apart from previous models: a redesigned softer and more conformable lobe, which adapts to various LAA anatomies, and an outer disc that acts as an additional sealing layer. According to Dr. Christopher Piorkowski, Chief Medical Officer at Abbott, this updated device is designed to perform consistently across the diverse anatomical variations encountered in clinical practice.

The Importance of the Left Atrial Appendage

The left atrial appendage is critical in understanding AFib since it can cause blood to pool, leading to clot formation. These clots can travel to the brain, drastically increasing the risk of stroke. By effectively closing this appendage, the Amulet 360 device plays a pivotal role in stroke prevention, offering an alternative to long-term anticoagulation therapy, which carries its own risks of bleeding complications.

Conclusion

As Abbott continues to refine its offerings to manage AFib and reduce stroke risk, the Amulet 360™ stands out as a promising option for patients. The one-year results from the VERITAS trial reinforce the device's safety and effectiveness, thus expanding the treatment options available for those affected by this condition. For a healthcare system grappling with the impacts of atrial fibrillation, the advancements represented by the Amulet 360 could signify a transformative step towards better patient care and outcomes.

Next steps will include further evaluations to determine how this device can be best integrated into existing AFib management protocols. With promising results on the horizon, Abbott remains dedicated to enhancing cardiovascular treatments through research and innovation.